Cargando…
A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling
Blocking the activity of cytokines is an efficient strategy to combat inflammatory diseases. Interleukin-6 (IL-6) fulfills its pro-inflammatory properties via its soluble receptor (IL-6 trans-signaling). The selective trans-signaling inhibitor olamkicept (sgp130Fc) is currently in clinical developme...
Autores principales: | Lokau, Juliane, Garbers, Yvonne, Grötzinger, Joachim, Garbers, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571719/ https://www.ncbi.nlm.nih.gov/pubmed/34765926 http://dx.doi.org/10.1016/j.isci.2021.103309 |
Ejemplares similares
-
Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)
por: Schulte, Dominik M., et al.
Publicado: (2022) -
Coding variants of the interleukin-11 receptor with reduced protein maturation show protease-dependent trans-signaling and transduce normal STAT3 signaling
por: Kespohl, Birte, et al.
Publicado: (2022) -
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells
por: Lokau, Juliane, et al.
Publicado: (2020) -
Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation
por: Lokau, Juliane, et al.
Publicado: (2016) -
Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling
por: Flynn, Charlotte M., et al.
Publicado: (2019)